Company Profile For BioMimetic Therapeutics, Inc.

BioMimetic Therapeutics, Inc. (BioMimetic) develops and commercializes products to stimulate the body’s natural tissue regenerative process. The Company’s protein therapeutic-device combination products are used for the treatment of musculoskeletal injuries and conditions affecting bones, tendons, ligaments, and cartilage. The Company’s platform regenerative technology, which incorporates a potent version of one of the body’s natural key stimulators of tissue repair, may offer physicians advanced biological solutions to actively stimulate tissue healing and regeneration. The Company focuses on developing GEM 21S technology to stimulate tissue healing in orthopedic applications (such as distal radius, or wrist, fractures and fusions of the bones in the foot and ankle to eliminate chronic pain from trauma or arthritis), and potentially spine and sports injury applications.

BRIEF: For the nine months ended 30 September 2009, BioMimetic Therapeutics, Inc.'s revenues decreased 18% to $1.1M. Net loss totaled $22.3M vs. an income of $4.2M. Revenues reflect a decrease in royalty income, lower sublicense fee income and the absence of other income. Net loss reflects an increase in patent license fee amortization, the presence of interest expenses and the absence of gain on disposal of equipment.